PSMA tracers are used in staging and re-staging prostate cancer, while somatostatin-targeting peptides (e.g. [68Ga]Ga-DOTA-TOC and -TATE) or [18F]DOPA are widely employed in neuroendocrine tumours [84–86]. This evidence concerns the gene FOLH1 and neuroendocrine neoplasm.